



All

News

Shopping

Images

Videos

More

Settings

Tools

About 9,600 results (0.71 seconds)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin ...

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC)

by S Pol - 2016 - Cited by 10 - Related articles

4 Mar 2016 - The **treatment of hepatitis C virus** has changed dramatically with the rapid ... their use without any dose adjustment in patients with chronic **kidney** disease. ... It is given once daily, and has a **good safety** profile.^{5,6} It has a **high** barrier of **sofosbuvir** + **daclatasvir** is efficient in liver **transplant recipients**.^{20,21} ...

Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/26587971>

by N Kamar - 2016 - Cited by 48 - Related articles

20 Nov 2015 - **Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation**. ... **sofosbuvir**-based regimen to **treat** chronic HCV **infection in kidney transplant recipients**. ... weeks (n = 6), **sofosbuvir** plus ribavirin (n = 3); **sofosbuvir** plus **daclatasvir** (n = 4); **sofosbuvir** ...

Hepatitis C virus infection and chronic kidney disease: Time for ...

[www.journal-of-hepatology.eu/article/S0168-8278\(16\)30273-2/pdf](http://www.journal-of-hepatology.eu/article/S0168-8278(16)30273-2/pdf)

by P Cacoub - 2016 - Cited by 3 - Related articles

because of poor **efficacy** and tolerance. Today, new direct acting antiviral (DAA) **treatments** lead to **HCV cure** in most patients with a very **good safety** profile.

Full Reviews An update on the management of hepatitis C virus ...

<https://academic.oup.com/ndt/article-pdf/32/1/32/9675101/gfw023.pdf>

by S Pol - 2017 - Cited by 5 - Related articles

patients with stage 4–5 chronic kidney disease while awaiting ... The **treatment of hepatitis C virus** (HCV) **infection** has pro- ... have a **high** antiviral potency (SVR >90%) and a fair tolerance SVR in **kidney transplant recipients treated with sofosbuvir**- the available data for **efficacy** and **safety** of the following DAAs

21

Name of Journal: *World Journal of Gastroenterology***Manuscript NO:** 34887**Manuscript Type:** ORIGINAL ARTICLE**Prospective Study**

12

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infectionXue Y *et al.* SOF and DCV for Kidney-transplantation Patients

Yan Xue, Li-Xin Zhang, Lei Wang, Tao Li, Yun-Dong Qu, Feng Liu

Match Overview

1	Internet 316 words crawled on 18-Jun-2017 www.wjgnet.com	9%
2	Crossref 99 words Kamar, N., O. Marion, L. Rostaing, O. Cointault, D. Ribes, L. Lavayssière, L. Esposito, A. Del Bello, S. Métivier, K. Ba	3%
3	Internet 63 words crawled on 28-Nov-2016 pdfs.semanticscholar.org	2%
4	Crossref 54 words Ming V. Lin, Meghan E. Sise, Martha Pavlakis, Beth M. Amundsen, Donald Chute, Anna E. Rutherford, Raymond T. C	2%
5	Crossref 43 words Beinhardt, Sandra, Ramona Al Zoairy, Peter Ferenci, Karin Kozbial, Clarissa Freissmuth, Rafael Stern, Albert Friedrich	1%
6	Internet 31 words crawled on 04-Sep-2016 www.science.gov	1%
7	Internet 22 words crawled on 02-Nov-2016 www.diagnosticimaging.com	1%
8	Crossref 22 words L. Wang. "Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical stud ...	1%
9	Internet 18 words crawled on 15-Jun-2017	1%

找到约 9,650 条结果 (用时 0.65 秒)

Daclatasvir-sofosbuvir combination therapy with or without ribavirin ...

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者 : S Pol - 2016 - 被引用次数 : 13 - 相关文章

2016年3月4日 - The **treatment** of **hepatitis C virus** has changed dramatically with the rapid advent of ... **daclatasvir** has demonstrated a **high** level of antiviral **efficacy** and HIV-HCV genotype 1-infected patients, with **good** tolerance and no impact on ... of **sofosbuvir** + **daclatasvir** is efficient in liver **transplant recipients**.20,21 ...

Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225154/> - 翻译此页

作者 : N Gamal - 2016 - 相关文章

2016年11月3日 - **Hepatitis C virus** (HCV) **infection** is a growing public health concern, with 184 ... In particular, **treatment** with **daclatasvir** (DCV) has yielded **high** rates of ... with other antivirals of a different class, such as **sofosbuvir**. The study included 97 liver **transplant recipients**, of which 93% had Gt 1 HCV **infection** and ...

Anti-hepatitis C virus drugs and kidney - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114471/> - 翻译此页

作者 : P Carrier - 2016 - 被引用次数 : 2 - 相关文章

2016年11月18日 - The **renal** toxicity of these new drugs was not a **safety** signal in clinical ... Finally, chronic **hepatitis C** is the most commonly seen **viral infection** in shown **good** results in terms of **efficacy**, tolerance and **medication** interactions[90,131]. ... **transplant** patients who were **treated** with **sofosbuvir** and **daclatasvir**, ...

Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat ...

onlinelibrary.wiley.com/doi/10.1111/ajt.13518/full ▼ 翻译此页

作者 : N Kamar - 2016 - 被引用次数 : 55 - 相关文章

2015年11月20日 - **Efficacy** and **Safety** of **Sofosbuvir**-Based Antiviral **Therapy** to **Treat** Hepatitis C ... regimen to **treat** chronic HCV **infection** in **kidney transplant recipients**. ... **Hepatitis C virus** (HCV)